{"symbol":"GILD","fiscalQuarter":"Q1-2026","reportDate":"2026-05-07","reportTime":"AMC","status":"reported","company":{"name":"Gilead Sciences, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/GILD/earnings/Q1-2026","estimates":{"consensusEps":1.9104,"consensusRevenue":6929.17,"epsLow":1.74,"epsHigh":2.06,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases, particularly in the fields of HIV, liver diseases, and oncology. With a market cap of $169 billion, Gilead plays a significant role in the healthcare sector, addressing critical health challenges and advancing treatment options.","keyMetrics":[{"name":"EPS","why":"Earnings per share is a key indicator of profitability and will show how well Gilead is managing costs and generating income.","consensus":"$1.91"},{"name":"Revenue","why":"Total revenue reflects the company's sales performance and growth trajectory, which is crucial for investor confidence.","consensus":"$6.9B"}],"lastQuarterRecap":{"summary":"In Q4 2025, Gilead reported an EPS of $1.86, exceeding expectations by 1.92%. However, the stock dropped 2.93% the following day, indicating market caution despite the earnings beat.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Gilead to report solid earnings this quarter, with a consensus EPS of $1.91 and revenue of $6.9 billion. Investors will be closely watching for any signs of growth in key therapeutic areas.","bullCase":"If Gilead exceeds EPS and revenue expectations, it could signal strong demand for its products and a positive outlook for future growth, potentially boosting investor confidence.","bearCase":"Conversely, if Gilead misses estimates or provides weak guidance, it could raise concerns about its market position and future profitability, leading to a negative reaction."},"optionsSignal":{"impliedMove":"4.88%","context":"The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility."},"earningsTrackRecord":[{"quarter":"Q4-2025","epsSurprise":"+1.92%","reaction":"-2.93%"},{"quarter":"Q3-2025","epsSurprise":"+14.62%","reaction":"-0.05%"},{"quarter":"Q2-2025","epsSurprise":"+0.80%","reaction":"+0.00%"},{"quarter":"Q1-2025","epsSurprise":"+3.31%","reaction":"-0.22%"},{"quarter":"Q4-2024","epsSurprise":"+13.91%","reaction":"+0.69%"},{"quarter":"Q3-2024","epsSurprise":"+28.01%","reaction":"+1.63%"},{"quarter":"Q2-2024","epsSurprise":"+25.08%","reaction":"+2.15%"},{"quarter":"Q1-2024","epsSurprise":"+11.47%","reaction":"-2.70%"}],"pivotalQuestions":[{"question":"Will Gilead's EPS exceed the consensus estimate of $1.91?","whyItMatters":"A beat on EPS would reinforce confidence in Gilead's profitability and growth potential, impacting stock performance."},{"question":"What guidance will Gilead provide regarding future revenue growth?","whyItMatters":"Future revenue guidance will be critical for investor sentiment, as it indicates the company's outlook in a competitive market."}],"thesisBreakLevels":{"bullTrigger":"Exceeding an EPS of $1.91 and revenue of $6.9 billion would confirm a strong performance.","bearTrigger":"Falling short of the consensus EPS and revenue expectations would signal potential challenges ahead.","context":"The market is focused on Gilead's ability to maintain profitability and growth in a competitive biotechnology landscape."},"scenarioPlaybook":{"beatAndRaise":"If Gilead beats expectations, history suggests the stock could see a positive reaction, potentially around a 1.3% move upwards.","inLineCautious":"If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess future growth.","miss":"Should Gilead miss estimates, history indicates a potential drop, with an average reaction of around -0.18% when they beat."},"whatTheStreetIsMissing":{"thesis":"The Street may underestimate Gilead's potential for revenue growth in emerging markets, where demand for its therapies is increasing.","supportingPoints":["Recent insider selling may indicate a lack of confidence in the near-term performance, which could affect investor sentiment.","Options pricing suggests a larger move than historical averages, indicating heightened uncertainty that may not align with actual performance."],"riskToConsensus":"If Gilead's revenue growth in emerging markets exceeds expectations, it could challenge the current consensus."},"whatToListenFor":["Any updates on new product launches or pipeline developments.","Details on revenue performance from key therapeutic areas.","Management's outlook on market conditions and competitive landscape.","Insights into cost management and operational efficiency.","Any commentary on international market expansion efforts."],"metaDescription":"Gilead Sciences (GILD) reports Q1 2026 earnings May 7. Analysts expect $1.91 EPS on $6.9B revenue. Here's what to watch."},"postBrief":{"headline":"Gilead Sciences Beats on EPS, Stock Down 1.64%","keyNumbers":[{"metric":"EPS","actual":"$2.03","expected":"$1.91","surprise":"+7.69%"},{"metric":"Revenue","actual":"N/A","expected":"$6.9B","surprise":"N/A"}],"managementCommentary":{"tone":"Unknown","keyQuotes":[],"summary":"No transcript is on record for this earnings call, so the analysis is based solely on numerical results."},"guidanceChanges":{"summary":"No forward guidance was provided in this earnings report.","changes":[]},"whatItMeans":"Gilead Sciences reported better-than-expected earnings per share, but did not provide revenue figures or future guidance. The stock reacted negatively, declining by 1.64%, which may reflect investor concerns over the lack of revenue details and future outlook.","metaDescription":"Gilead Sciences (GILD) Q1 2026 earnings: EPS beat by 7.69%, revenue not reported. Stock down 1.64%. Full breakdown."}}